In a nutshell This study looked at pomalidomide (Pomalyst) for patients with multiple myeloma (MM) which had returned after previous treatment. It found that adding pomalidomide to Vd (bortezomib, dexamethasone) led to better outcomes than Vd alone. Some background MM is a blood cancer in adults. Myeloma cells are cancerous versions of plasma cells,...
Read More
In a nutshell This study aimed to review the safety and effectiveness of three chimeric antigen receptor (CAR) T cell therapies, axicabtagene ciloleucel (AXI; Yescarta), tisagenlecleucel (TIS; Kymriah), and lisocabtagene maraleucel (LIS; Breyanzi), for the treatment of blood cancers. This study concluded that AXI and TIS showed very good...
Read More
In a nutshell This study evaluated the safety and effectiveness of teclistamab (JNJ-64007957) for patients with recurrent or unresponsive multiple myeloma (MM). This study concluded that this treatment was safe and showed promising effectiveness for these patients. Some background Multiple myeloma is a type of cancer of the bone marrow that can...
Read More
In a nutshell This study investigated how people with myeloma responded to vaccines against COVID-19. It found that roughly half of the patients with multiple myeloma (MM) and most patients with other types of myeloma had protection against serious illness after the vaccine. The response to the vaccine was weaker for patients using certain treatments,...
Read More
In a nutshell This study evaluated the effectiveness and safety of a venetoclax (Venclexta), daratumumab (Darzalex), and dexamethasone (Decadron combination with or without bortezomib (Velcade) in patients with relapsed or refractory (RR) multiple myeloma (MM). The authors concluded that these treatment combinations produced high...
Read More
In a nutshell This study assessed the effectiveness of netupitant/palonosetron (NEPA; Akynzeo) in preventing nausea and vomiting in patients with multiple myeloma (MM) while receiving high-dose melphalan (HDM; Alkeran) and autologous stem cell transplantation (ASCT). The data showed that NEPA, without dexamethasone (DXM; Decadron), was...
Read More
In a nutshell This study assessed the effects of administering personalized doses of VCD (bortezomib, cyclophosphamide, and dexamethasone) followed by VTD (bortezomib, thalidomide, and dexamethasone) in older patients with newly diagnosed multiple myeloma (NDMM). The data showed high response rates and safety in these patients. Some background...
Read More
In a nutshell This study investigated the effectiveness and safety of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy for patients with previously treated relapsed or refractory (r/r) multiple myeloma (MM). The data showed that a single dose of cilta-cel was safe and effective for the treatment of these...
Read More
In a nutshell This study evaluated the effectiveness and safety of adding isatuximab (Sarclisa) to carfilzomib (Kyprolis) and dexamethasone (Decadron) combination (Kd) for patients with previously treated relapsed multiple myeloma (MM). The data showed that adding isatuximab to the Kd regimen reduced the risk of disease progression or death for these...
Read More
In a nutshell This study reported the safety and effectiveness of a combination of carfilzomib (Kyprolis), bendamustine (Treanda), and dexamethasone (Decadron) for patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that a combination of carfilzomib, bendamustine, and dexamethasone (CBd) showed promising...
Read More
In a nutshell This study compared the outcomes of proteasome inhibitors (PIs) versus immunomodulators (IMs) as maintenance therapy for patients with newly diagnosed MM. The data showed that PIs maintenance increased the survival outcomes compared to IMs in these patients. Some background Multiple myeloma (MM) is a type of cancer that comes from blood...
Read More
In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including multiple myeloma (MM), that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment. This trial is...
Read More
